HomeCompareTGLVY vs JNJ

TGLVY vs JNJ: Dividend Comparison 2026

TGLVY yields 0.62% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.5K in total portfolio value· pulled ahead in Year 5
10 years
TGLVY
TGLVY
● Live price
0.62%
Share price
$0.59
Annual div
$0.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.06
Full TGLVY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TGLVY vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGLVYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGLVY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TGLVY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGLVY
Annual income on $10K today (after 15% tax)
$52.38/yr
After 10yr DRIP, annual income (after tax)
$0.05/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGLVY + JNJ for your $10,000?

TGLVY: 50%JNJ: 50%
100% JNJ50/50100% TGLVY
Portfolio after 10yr
$25.0K
Annual income
$2,344.73/yr
Blended yield
9.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TGLVY
No analyst data
Altman Z
3.8
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGLVY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGLVYJNJ
Forward yield0.62%2.13%
Annual dividend / share$0.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$19.8K$30.3K
Annual income after 10y$0.06$4,689.40
Total dividends collected$62.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TGLVY vs JNJ ($10,000, DRIP)

YearTGLVY PortfolioTGLVY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,731$30.81$10,592$272.30+$139.00TGLVY
2$11,497$15.45$11,289$357.73+$208.00TGLVY
3$12,310$7.74$12,123$472.89+$187.00TGLVY
4$13,176$3.87$13,141$629.86+$35.00TGLVY
5← crossover$14,100$1.94$14,408$846.81$308.00JNJ
6$15,088$0.97$16,021$1,151.60$933.00JNJ
7$16,144$0.48$18,122$1,588.22$2.0KJNJ
8$17,275$0.24$20,930$2,228.20$3.7KJNJ
9$18,484$0.12$24,792$3,191.91$6.3KJNJ
10$19,778$0.06$30,274$4,689.40$10.5KJNJ

TGLVY vs JNJ: Complete Analysis 2026

TGLVYStock

Top Glove Corporation Bhd. engages in the investment holding and provision of management services in Malaysia. The company offers medical examination, surgical, vinyl, and nitrile gloves; concentrate and synthetic latex, formers, chemicals and chemical compounds, rubber dental dams, exercise bands, condoms, and rubber related products; packaging materials, boxes, and cartons; and disposable and medical face masks, engineering parts and rubber glove machinery, functional fillers, healthcare products, and homecare and personal care products. It also provides property investment, consultancy services, and electrical engineering works; clinical and specialist medical services; analytical, emergency medical, advisory, general management, and value added services; management services in plantation sector, and processing of plantation produce; general trading; and industrial forest plantation, as well as forestry and industry services. In addition, the company trades in healthcare related products; distributes medical devices and other hospital related products; operates as a special purpose vehicle solely for issuance of Perpetual Sukuk; organizes in-house trainings and public trainings/programs; and establishes and maintains fitness related business, including healthcare, slimming centers, gymnasiums, and other related activities. Further, it generates and supplies energy and electricity using biomass technology; and offers e-commerce services for glove trading and other healthcare products. The company also exports its products to 195 countries worldwide. Top Glove Corporation Bhd. was founded in 1991 and is headquartered in Shah Alam, Malaysia.

Full TGLVY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TGLVY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGLVY vs SCHDTGLVY vs JEPITGLVY vs OTGLVY vs KOTGLVY vs MAINTGLVY vs ABBVTGLVY vs MRKTGLVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.